Fact Sheet: BENZOAK® (sedative/anesthetic) INAD 11-740

for detailed information, see INAD study protocol, use link on the left
last updated: 1 December 2011

The following links are specific to:
BENZOAK
®

Drug summary & history

List of FDA-Approved Drugs

Drug forms to be completed

INAD study protocol

Material Safety Data Sheet
(MSDS)

Study Summaries

What's the status of this drug's
approval

Print this drug fact sheet

Print all drug fact sheets

Sign-up via the INAD Program Management System (IPMS)

Information on EPA's National Pollutant Discharge Elimination System (NPDES) Permits

Guidelines for Preparing and Using BENZOAK®

Authorization & Categorical Exclusion Letters

Objective/purpose: Collect scientific data necessary to establish the effectiveness AND safety of BENZOAK® as an anesthetic/sedative in a variety of fish species under a variety of environmental conditions.
Drug name: BENZOAK® (20% benzocaine)
Source of drug:

Frontier Scientific, Inc.
195 South 700 West, P.O. Box 31
Logan, Utah 84323-0031 USA

Contact: Shelley Tiev or Holly Seamons
Phone: 435-753-1901
FAX: 435-753-6731
email: sales@frontiersci.com

Target pathogen(s): not applicable
Method of administration: Immersion; standing bath treatment only
Treatment dosage:

10 – 100 mg benzocaine per L

Note: For sedation to handleable, a treatment dosage of 30-40 mg benzocaine per L is recommended for all species.

Treatment regimen:

Treatment duration is up to 15 minutes. Treatment duration will vary dependent upon species, water temperature, and level of sedation desired.

BENZOAK® should be applied as a single treatment event.

Withdrawal period:

72 hours.

No withdrawal period is required for fish that are not susceptible to legal harvest for a period of 72 hours post-treatment. Fish euthanized with Benzoak® must not be sent to slaughter or be otherwise available for food until the withdrawal period has been observed.

Required test parameters: Investigator must collect data documenting: 1) time to sedation; and 2) time to recovery from sedation. Investigator must also report general fish behavior and any adverse effects relating to treatment.
Limitations or restrictions on use:

Investigator must follow all instructions in the Study Protocol for INAD 11-740 regarding drug acquisition and handling, fish treatment and disposition, and data reporting requirements.

Drug discharge must be in compliance with local NPDES permitting requirements.

Required INAD fee: none
AADAP contact for other information: Ms. Bonnie Johnson, FWS - AADAP
Phone: 406-994-9905
Fax: 406-582-0242

email: bonnie_johnson@fws.gov
Disclaimer: Product and company names mentioned in this website, or mentioned in materials accessed via this website, are for informational purposes only. The mention of such does not imply endorsement by the Aquatic Animal Drug Approval Partnership, the U.S. Fish & Wildlife Service or any other organization of the U.S. Government.